Pharma channel feed – Endpoints News

Pharma channel feed

The gene therapy pricing debate gets real as Spark sets $850,000 charge for its pioneering drug

8 years ago

Chinese dealmaking: SARI nabs Italy’s NMS Group for $362M; Inovio retools deal with ApolloBio

8 years ago

Star drugs like BMS' Opdivo, AstraZeneca's Lynparza will get speedy OKs in China this year, new report predicts

8 years ago

The class of 2017's winners and losers: A year of 'nonstop scientific achievements' raises troubling issues

8 years ago

Celgene shares sink after another PhIII lymphoma flop and J&J steps up for the late-stage BCMA race

8 years ago

The FDA just approved the 46th new drug of the year — a record high for the past decade

8 years ago

J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO

8 years ago

Kymriah, Yescarta found 'cost-effective' in treating cancer, despite high price

8 years ago

Merck, Pfizer make a late — very late — arrival at the SGLT2 party for diabetes

8 years ago

A US senator calls out a little biotech for price gouging. But will it change anything?

8 years ago

With AveXis coming up in the rear view mirror, Biogen and Ionis go back to the drawing board on SMA

8 years ago

FDA rolls out an early and historic OK for Spark's pioneering gene therapy -- now let's talk price

8 years ago

Array joins Pfizer on anti-cancer combos, the latest in a string of binimetinib combinations

8 years ago

Stepping up behind Sanofi, Genentech rolls the DiCE on a new small molecule discovery pact

8 years ago

Aerie bags an early OK for its self-described blockbuster glaucoma drug Rhopressa, recruiting 100 reps

8 years ago

On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo

8 years ago

Severe job cuts at Teva incite massive worker strikes, shutting Israel down

8 years ago

What’s the big hurry, Novartis? Pharma giant scores a PRV shortcut for $130M

8 years ago

Boehringer antes up on a €627.5M deal for rights to Autifony’s schizophrenia drugs

8 years ago

Four months after patient death, FDA's hold lifted on Alnylam's fitusiran

8 years ago

Amicus CEO lobbied FDA to reverse FDA’s rejection of migalastat, claiming a delay of up to 7 years

8 years ago

Galapagos snags co-promotion rights on filgotinib — just before Gilead’s lock-up pact expires

8 years ago

Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs

8 years ago

The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate

8 years ago

First page Previous page 310 311 312313314 315 316 Next page Last page